Susquehanna International Group, LLP Corvus Pharmaceuticals, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 1,015,083 shares of CRVS stock, worth $5.04 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,015,083
Previous 218,962
363.59%
Holding current value
$5.04 Million
Previous $1.16 Million
356.57%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CRVS
# of Institutions
96Shares Held
39.9MCall Options Held
1.95MPut Options Held
462K-
Orbimed Advisors LLC San Diego, CA6.94MShares$34.5 Million0.98% of portfolio
-
Samlyn Capital, LLC New York, NY6.67MShares$33.1 Million0.56% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$16.3 Million18.22% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.03MShares$15.1 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$13.3 Million0.23% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $231M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...